Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies
Q Dong, H Bao, J Wang, W Shi, X Zou, J Sheng… - Frontiers in …, 2023 - frontiersin.org
In recent years, the prevalence of metabolic-associated fatty liver disease (MAFLD) has
reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the …
reached pandemic proportions as a leading cause of liver fibrosis worldwide. However, the …
MASLD and aspartame: are new studies in the horizon?
CM Sergi - Frontiers in Medicine, 2023 - frontiersin.org
Fatty liver disease has been on the rise in the past few decades, and there is no hope that it
will stop. The terminology change that has been recently proposed may not be sufficient to …
will stop. The terminology change that has been recently proposed may not be sufficient to …
NLRP-3 inflammasome: a key target, but mostly overlooked following SARS-CoV-2 infection
CM Sergi - Vaccines, 2022 - mdpi.com
The last two years have shown many political and scientific debates during the current
Coronavirus Disease 2019 (COVID-19) pandemic [1]. Hydroxychloroquine, an antimalarial …
Coronavirus Disease 2019 (COVID-19) pandemic [1]. Hydroxychloroquine, an antimalarial …